Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from USFDA for Niacin Extended-Release Tablets USP
Details : Niacin is indicated to reduce elevated total cholesterol (TC), LDL-C, Apo B and TG, also to increase HDL-C in patients with primary hyperlipidaemia and mixed dyslipidaemia.
Product Name : Niaspan-Generic
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 02, 2025
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial
Details : This trial is being conducted to evaluate the safety and tolerability of ATG-019 monotherapy or ATG-019 combined with niacin ER, for the treatment of advanced solid tumors or non-Hodgkin's lymphoma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : National Heart, Lung, and Blood Institute | Arizona Pharmaceuticals Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Niacin On Fatty Acid Trapping
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 14, 2013
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : National Heart, Lung, and Blood Institute | Arizona Pharmaceuticals Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 02, 2012
Lead Product(s) : Niacin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : University Hospital, Geneva | Swiss National Science Foundation | Fondation Ernest Boninchi | Swiss Heart Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 12, 2012
Lead Product(s) : Niacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : University Hospital, Geneva | Swiss National Science Foundation | Fondation Ernest Boninchi | Swiss Heart Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : US Department of Defense | The Sage Colleges | Women's College Hospital | Severna Park Health and Wellness Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Gulf War Illness: Evaluation of an Innovative Detoxification Program
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 27, 2012
Lead Product(s) : Niacin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : US Department of Defense | The Sage Colleges | Women's College Hospital | Severna Park Health and Wellness Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 11, 2011
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : National Health and Medical Research Council, Australia
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 12, 2011
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : National Health and Medical Research Council, Australia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 15, 2011
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 04, 2011
Lead Product(s) : Niacin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
